Pyrazinamide (PZA) is an important first-line drug for short-course chemotherapy against Mycobacterium tuberculosis. PZA is a prodrug whose activity requires amide hydrolysis to pyrazinoic acid (POA) by the mycobacterial enzyme, pyrazinamidase (PZAse). A recent report suggests that POA may act mainly against fatty acid synthetase (FAS) I, a eukaryotic-like enzyme present in M. tuberculosis [1] . PZAse is encoded by the pncA gene. PZA-resistant M. tuberculosis strains show loss of PZAse activity, correspondingly, the pncA gene, which was cloned and characterized by Scorpio et al., reportedly shows mutations [2] .
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by the Ministry of Health and Welfare after the World Health Organization recommended PZA for directly observed therapy for a short course (DOTS) in 1991 [3] . However, little is known about pncA gene mutations of M. tuberculosis strains in Japan [4] . We therefore studied pncA gene mutations in 30 Japanese clinical isolates of M. tuberculosis including some resistant to PZA.
All clinical isolates were identified by DAN-DNA hybridization assay [5] using a commercially available kit (DDH Mycobacteria ; Kyokuto Pharmaceuticals, Tokyo, Japan) according to the manufacturer's instructions. M. tuberculosis strain ATCC35828 (with a single G nucleotide absent at position 288 in the pncA gene), a PZA-sensitive M. tuberculosis strain ATCC27294 (H37Rv), and a PZAresistant M. bo is (BCG) strain ATCC 27289 (with a change from C to G at nucleotide position 169 in the 338 T. Endoh and others pncA gene) were obtained from the American Type Culture Collection (ATCC, Rockville, MD). These three strains were used as a negative and positive controls for mutations in the pncA gene.
PZA susceptibility testing was performed by the conventional agar proportion method [6] using Middlebrook 7H10 agar with oleic acid-albumin-dextrosecatalase (OADC) enrichment (pH 5n8 ; Difco Laboratories, Detroit, MI) and a liquid medium method [7] using Middlebrook 7H9 medium with albumindextrose-catalase (ADC) enrichment, (pH 5n6 ; Difco). Susceptibility to PZA was defined in terms of the minimum inhibitory concentration (MIC), the lowest PZA concentration able to inhibit more than 99 % of growth observed on the PZA-free control. To determine MIC, 7H10 agars containing 25 mg\l, 50 mg\l, and 100 mg\l of PZA or 7H9 liquid medium containing 100 mg\l and 400 mg\l of PZA were used. PZAse activity was assayed according to the method described by Wayne [8] , using a tube of 7H10 agar containing 100 mg\l of PZA and 2 g\l sodium pyruvate. Each isolate was compared to the known PZAse-positive strain (PZA-sensitive M. tuberculosis ATCC27297, H37Rv) and the negative strains (PZAresistant M. tuberculosis ATCC35828 and M. bo is ATCC27289). Among the 30 clinical isolates, 25 were sensitive to PZA (MIC less than 25 mg\l) and 5 were resistant (MIC 50 mg\l or more) by the agar proportion method ; 24 were sensitive to PZA (MIC less than 100 mg\l) and 6 were resistant (MIC at least 100 mg\l) by the liquid medium method. Three clinical isolates (nos 28-30) had an MIC of at least 100 mg\l by the agar proportion method and also an MIC of 400 mg\l by the liquid medium method. PZAse activity was not detected in these three isolates ; the other 27 isolates were PZAse-positive.
In all 30 clinical isolates and in the control strains, polymerase chain reaction (PCR)-single conformation polymorphism (SSCP) analysis was performed for rapid detection of mutations in the pncA gene. The pncA gene was amplified as four separate partial sequences to optimize detection sensitivity by SSCP (all amplified PCR products had fewer than 200 bp) [9] . Two sets of primers were described previously [10] , while two other sets of primers were constructed to amplify fragments of the pncA gene extending from positions k102 to 110, and from 401 to j55 based upon the GenBank sequence (accession number AL02189 ; Table 1 ). The PCR mixture contained the following reagents : 1iPCR buffer, 0n25 m of dNTPs, 5 pmol of primers, 2n5-m concentration of MgCl # , 10 µg of genomic DNA, and 2n5 U of Taq DNA polymerase. PCR conditions programmed with an Applied Biosystems model 9600 thermal cycler (Foster, CA) were 95 mC for 5 min followed by 30 cycles at 95 mC for 30 sec, 55 mC for 30 sec, and 72 mC for 30 sec. SSCP analysis was performed according to a modified method described by Scorpio et al. [10] . Briefly, 0n5 to 1n0 µg of PCR products were denatured with 9 volumes of formamide dye solution (95 % formamide, 10 m sodium hydroxide, 20 m ethylenediaminetetraacetic acid (EDTA), 0n05 % bromophenol blue, and 0n05 % xylene cyanol FF) at 95 mC, and then cooled and maintained on ice. Denatured PCR products were loaded onto a 6 % polyacrylamide gel containing 5 % glycerol (16 by 20 cm ; acrylamide : bis-acrylamide, 49 : 1). Electrophoresis was performed in 0n5iTBE buffer containing 0n05  Tris, 0n045  Boric acid, 0n0005  EDTA at a constant voltage of 150 V (5 h, 20 mC). Bands on the gels were visualized by silver staining method (Plus One DNA silver staining kit, Amersham Pharmacia Biotech, Uppsala, Sweden). SSCP band patterns obtained were compared with those of control strains. SSCP band patterns of clinical M. tuberculosis isolate no. 28 (in the primer set P1 region), no. 29 (in the primer set P3 region), and no. 30 (in the primer set P1 region) differed from those of PZA-susceptible M. tuberculosis strain ATCC27294 (H37Rv), as show in Figure 1 .
Other clinical isolates did not show any difference in SSCP band patterns compared with PZA-sensitive M. tuberculosis strain ATCC27294 (H37Rv). The positive control strains for pncA gene mutation, ATCC27289 (with a change from C to G at position 169) and ATCC35828 (with a single nucleotide deleted at position 288) had SSCP band patterns that differed from that of the positive control strain in the primer set P2 region (from position 91-270) and in the primer set P3 region (position 251-420), respectively (Fig. 1) . In addition, PCR products amplified using same pncA primers as for PCR-SSCP were cut from the gel and purified with a QIAquick gel extraction kit (Qiagen, Valencia, CA). Sequencing reactions were performed with a DNA sequencing kit (BigDye terminator cycle sequencing Ready Reaction ; Applied Biosystems) using 10 ng of purified PCR products and 3n2 pmol of primers. After products were purified by Centri-sep spin columns (Applied Biosystems), the purified products were directly sequenced using a genetic analyzer (ABI PRISM 310 ; Applied Biosystems). The sequences were compared with the published sequence of pncA using sequence similarity search software (Basic Local Alignment Search Tool, or BLAST) from the National Center for Biotechnology Information (NCBI, Bethesda, MD). Results of PCR-direct sequence analysis of pncA gene are shown in Table 2 . Clinical isolate no. 28 had a Tto-C change at position 11, leading to a Leu4 4 Ser amino-acid substitution ; Isolate no. 29 had an 8-bp deletion at position 382 ; Isolate no. 30 had an A-to-C change at position 29, leading to a Gln10 4 Pro amino-acid substitution. These mutation positions determined by PCR-direct sequencing were consistent with the amplified regions showing abnormal SSCP band patterns. Mutations of the pncA gene in positive control strains were confirmed by PCR-direct sequence analysis (Table 2) .
In this study, all PZA-sensitive clinical M. tuberculosis isolates showed PZAse activity and no mutation in the pncA gene, while three PZA-resistant isolates (nos 28-30) had mutations in the pncA gene and no PZAse activity. These three isolates showed high MIC for PZA (MIC at least 100 mg\l by the 7H10 agar proportion method and 400 mg\l by the 7H9 liquid medium method). Glenn et al. [11] also reported that M. tuberculosis with a pncA gene mutation showed similarly high MICs for PZA. In addition, our three PZA resistant isolates showed resistance to several additional antituberculous drugs such as isoniazid, rifampin, streptomycin, and ethambutol. Our results are consistent with previous reports that PZA-resistant M. tuberculosis strains with pncA gene mutations show multiple-drug resistance.
Three of our isolates (nos 9, 15, 18) showed a discrepancy between the two MIC determinations, and were identified as PZA-resistant by only one method. In addition, our isolate no. 3 showed an MIC of 50 mg\l by the 7H10 agar proportion method and 100 mg\l by the 7H9 liquid medium method, qualifying as a PZA-resistant strain by both assays. All four isolates showed PZAse activity, and none had a mutation in the pncA gene. Notably, conventional susceptibility testing for PZA is difficult to perform because PZA is most active at a pH of approximately 5n5, which in itself, inhibits growth of M. tuberculosis [7, 12, 13] . These four isolates may have had important mutations apart from the pncA gene, they may have shown false resistance because of difficulties of culture under acidic conditions.
We demonstrated three different mutations of the pncA gene in three clinical M. tuberculosis isolates from Japanese patients : isolate no. 28 had a T-to-C change at position 11, leading to a Leu4 4 Ser aminoacid substitution ; no. 29 had an 8-bp deletion at position 382 ; and no. 30 had an A-to-C change at position 29, leading to a Gln10 4 Pro amino-acid substitution. Although the significance of pncA gene mutations in M. tuberculosis is not altogether clear, a single-nucleotide mutation was noted frequently in PZA-resistant M. tuberculosis in previous reports. Approximately 40 % of distinct amino acid substitutions involved replacement with a proline residue. Insertion or deletion of multiple nucleotides tended to be found in the downstream portion of the pncA gene [2, 10, 11, [14] [15] [16] [17] [18] [19] [20] . In our three clinical PZA-resistant M. tuberculosis isolates with pncA gene mutations, two had single-nucleotide mutations (Leu4 to Ser or Gln10 to Pro), while one had a deletion in the downstream portion of the pncA gene that has not been described previously. This deletion is close to the regions (Ala-134, Thr-135, and Cys-138) which is considered the key residues for hydrolysis of PZA and resulted in frameshift [21] .
Davies et al. concluded that pncA genotype determinations in PZA-resistant M. tuberculosis by methods such as PCR-SSCP and PCR-direct sequencing cannot reliably determine the mechanism of resistance, because these examine only one possible cause [22] . A PZA-resistant M. tuberculosis isolates does not necessarily have mutations in the pncA gene ; the frequency of pncA gene mutation has been estimated to be 72-97 % in PZA-resistant clinical isolates [2, 10, 18, 19] . In addition, culture methods may induce mutations in M. tuberculosis ; Scorpio et al. succeeded in inducing a mutation using 7H11 agar with 500 mg\l of PZA [10] .
Therefore, genotype determinations must be combined with phenotyping of PZA-resistant M. tuberculosis, such as PZAse activity assay and pyrazinamide susceptibility testing.
Until now, the brief history of antituberculous chemotherapy with PZA in Japan has included no reports concerning PZA resistance and pncA gene mutations. This is the first demonstration of pncA gene mutations in PZA-resistant M. tuberculosis strains isolated from Japanese patients. In addition, the deletion found in isolate no. 29 has not been described previously.
